Ερευνητικό υλικό ΕΚΠΑ

Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial

Αγγλικά

Δεν υπάρχει περίληψη

2015

Poveda, A.M.
Selle, F.
Hilpert, F.
Reuss, A.
Savarese, A.
Vergote, I.
Witteveen, P.
Bamias, A.
Scotto, N.
Mitchell, L.
Pujade-Lauraine, E.

Journal of Clinical Oncology

American Society of Clinical Oncology

33

32

3836-3838

bevacizumab; doxorubicin; paclitaxel; topotecan; antineoplastic agent; bevacizumab; doxorubicin; macrogol derivative; paclitaxel; platinum derivative; topotecan, adult; aged; cancer combination chemotherapy; cancer diagnosis; cancer recurrence; cancer resistance; controlled study; female; human; intention to treat analysis; Letter; major clinical study; open study; outcome assessment; ovary cancer; overall survival; phase 3 clinical trial; platinum resistant recurrent ovarian cancer; priority journal; progression free survival; quality of life; randomized controlled trial; analogs and derivatives; cancer grading; cancer staging; clinical trial; drug administration; drug resistance; Kaplan Meier method; middle aged; Ovarian Neoplasms; pathology; prognosis; risk factor; treatment outcome; tumor recurrence; very elderly, Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Prognosis; Risk Factors; Topotecan; Treatment Outcome

https://doi.org/10.1200/JCO.2015.63.1408

10.1200/JCO.2015.63.1408

https://pergamos.lib.uoa.gr/uoa/dl/object/3087637